CAS 475207-59-1
:Nexavar
Description:
Nexavar, with the CAS number 475207-59-1, is the trade name for sorafenib, a small molecule tyrosine kinase inhibitor used primarily in cancer treatment. It is characterized by its ability to inhibit multiple kinases involved in tumor cell proliferation and angiogenesis, including Raf kinases and receptor tyrosine kinases such as VEGFR and PDGFR. Sorafenib is typically administered orally and is known for its role in treating advanced renal cell carcinoma and hepatocellular carcinoma. The compound is a pale yellow to off-white solid, with a molecular formula that includes carbon, hydrogen, nitrogen, oxygen, and fluorine. Its mechanism of action involves disrupting the signaling pathways that promote cancer cell growth and blood vessel formation, thereby slowing tumor progression. Nexavar is often associated with side effects such as fatigue, diarrhea, and skin reactions, which are important considerations in patient management. Overall, sorafenib represents a significant advancement in targeted cancer therapies, offering a strategic approach to combat specific malignancies.
Formula:C21H16ClF3N4O3·C7H8SO3
InChI:InChI=1S/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)
InChI key:InChIKey=IVDHYUQIDRJSTI-UHFFFAOYSA-N
SMILES:O(C=1C=C(C(NC)=O)N=CC1)C2=CC=C(NC(NC3=CC(C(F)(F)F)=C(Cl)C=C3)=O)C=C2.S(=O)(=O)(O)C1=CC=C(C)C=C1
Synonyms:- 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1)
- 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, mono(4-methylbenzenesulfonate)
- 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate
- BAY 43-9006 mono-p-tosylate
- Bay 54-9085
- N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea Tolsylate
- Nexavar
- Sorafenib TsOH salt
- Sorafenib p-toluenesulfonate
- Sorafenib-D3
- Sorafenib tosylate
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 19 products.
Sorafenib Tosylate
CAS:Formula:C21H16ClF3N4O3·C7H8O3SPurity:>98.0%(T)(HPLC)Color and Shape:White to Light yellow powder to crystalMolecular weight:637.03Sorafenib Tosylate
CAS:Compounds containing an unfused pyridine ring in the structure, nesoiFormula:C21H16ClF3N4O3·C7H8O3SColor and Shape:White Brown PowderMolecular weight:636.105724-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-methylbenzene-1-sulfonic acid
CAS:Formula:C28H24ClF3N4O6SPurity:98%Color and Shape:SolidMolecular weight:637.0266Sorafenib tosylate
CAS:<p>Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).</p>Formula:C21H16ClF3N4O3·C7H8O3SPurity:99.24% - 99.94%Color and Shape:White To Off-White Crystalline PowderMolecular weight:637.03Sorafenib tosylate
CAS:Formula:C21H16ClF3N4O3·C7H8O3SPurity:≥ 98.0% (dried basis)Color and Shape:White, off-white or pale yellow-brown powderMolecular weight:637.03Sorafenib Tosylate
CAS:Formula:C21H16ClF3N4O3·C7H8O3SColor and Shape:Off-White SolidMolecular weight:464.83 172.20Sorafenib Tosylate
CAS:Controlled ProductFormula:C21H16ClF3N4O3·C7H8O3SColor and Shape:NeatMolecular weight:637.03Sorafenib tosylate
CAS:<p>Sorafenib tosylate</p>Formula:C21H16ClF3N4O3·C7H8O3SPurity:99%Color and Shape: off-white solidMolecular weight:637.03g/molSorafenib Tosylate
CAS:Controlled ProductFormula:C21H16ClF3N4O3·C7H8O3SColor and Shape:NeatMolecular weight:637.03Sorafenib tosylate
CAS:<p>Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib tosylate has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.</p>Formula:C21H16ClF3N4O3•C7H8O3SPurity:Min. 95%Color and Shape:Off-White PowderMolecular weight:637.03 g/molSorafenib tosylate - Bio-X ™
CAS:<p>Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib tosylate has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib tosylate also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.<br>Sorafenib tosylate is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready to use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.</p>Formula:C21H16ClF3N4O3•C7H8O3SPurity:Min. 95%Color and Shape:PowderMolecular weight:637.03 g/molSorafenib, p-Toluenesulfonate Salt
CAS:Formula:C35H30F3N7O4SPurity:98%Color and Shape:SolidMolecular weight:701.73
![4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA0035M4.jpg&w=3840&q=75)
